Related Experiment Videos
A radioimmunoassay for circulating human proinsulin.
Diabetes
|January 1, 1985
Summary
A new radioimmunoassay for human proinsulin (hPl) was developed for measuring hPl levels in serum and plasma. This assay, utilizing biosynthetic hPl, demonstrates high specificity and sensitivity, enabling accurate quantification in various subject groups.
Area of Science:
- Biochemistry
- Immunology
- Endocrinology
Background:
- Accurate measurement of human proinsulin (hPl) is crucial for understanding glucose metabolism and diabetes.
- Existing assays may lack the specificity or sensitivity required for certain applications.
Purpose of the Study:
- To develop and validate a highly specific and sensitive radioimmunoassay for human proinsulin (hPl).
- To enable accurate quantification of hPl in serum and plasma samples from normal and diabetic individuals.
Main Methods:
- Development of a radioimmunoassay using biosynthetic human proinsulin (hPl) as immunogen, standard, and tracer.
- Antiserum adsorption with insulin and C-peptide conjugated to Sepharose to enhance specificity.
- Establishment of a quantitative extraction procedure for proinsulin-like material (PLM) from plasma using insulin antibody-Sepharose.
Main Results:
- The developed radioimmunoassay exhibited high specificity, with cross-reactivities to insulin and C-peptide below 0.2%.
- The assay demonstrated suitable sensitivity (10-150 fmol/tube) for measuring hPl during biosynthetic hPl infusions.
- Parallel dilution curves were observed for serum samples from normal and type I diabetic subjects, validating the assay's performance.
- A method for extracting PLM from plasma allowed for the measurement of endogenous hPl levels.
Conclusions:
- A specific and sensitive radioimmunoassay for human proinsulin has been successfully developed.
- The assay is suitable for measuring exogenous hPl and, with an extraction procedure, endogenous hPl levels.
- This tool facilitates further research into proinsulin dynamics in normal physiology and diabetes.